MYLAN-LOSARTAN HCTZ TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE

থেকে পাওয়া:

MYLAN PHARMACEUTICALS ULC

এটিসি কোড:

C09DA01

INN (আন্তর্জাতিক নাম):

LOSARTAN AND DIURETICS

ডোজ:

100MG; 12.5MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

LOSARTAN POTASSIUM 100MG; HYDROCHLOROTHIAZIDE 12.5MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

30/100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0233168003; AHFS:

অনুমোদন অবস্থা:

CANCELLED POST MARKET

অনুমোদন তারিখ:

2018-05-10

পণ্য বৈশিষ্ট্য

________________________________________________________________________________________________________
MYLAN-LOSARTAN HCTZ
Page 1 of 42
PRODUCT MONOGRAPH
Pr
MYLAN-LOSARTAN HCTZ
losartan potassium and hydrochlorothiazide tablets
50 mg/12.5 mg, 100 mg/12.5 mg and 100 mg/25 mg
Manufacturer’s standard
Angiotensin II Receptor Antagonist and Diuretic
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Revision:
August 09, 2013
SUBMISSION CONTROL NUMBER: 166901
________________________________________________________________________________________________________
MYLAN-LOSARTAN HCTZ
Page 2 of 42
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................... 3
SUMMARY PRODUCT INFORMATION
................................................................ 3
INDICATIONS AND CLINICAL USE
......................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................
4
ADVERSE REACTIONS
.............................................................................................
8
DRUG INTERACTIONS
...........................................................................................
11
DOSAGE AND ADMINISTRATION
......................................................................
16
OVERDOSAGE
..........................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
................................................... 18
STORAGE AND STABILITY
..................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................... 21
PART II: SCIENTIFIC INFORMATION
.............................................................. 23
PHARMACEUTICAL INFORMATION
................................................................. 2